In this study, researchers harnessed crowdsourcing and open science to develop new antivirals against SARS-CoV-2, focusing on its main protease, Mpro. Their approach led to the discovery of potent compounds, including one with high efficacy in cell lines and cross-reactivity against various COVID-19 variants, demonstrating the potential of collaborative and transparent drug discovery in tackling global health crises.
Bayer details data from two Phase 3 trial wins for menopause symptom drug
Bayer shared more data on its menopause symptom drug elinzanetant, which demonstrates how the treatment triumphed over placebo in two of three Phase 3 trials.
May 18, 2024